Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE) gapped up before the market opened on Friday . The stock had previously closed at $15.66, but opened at $16.36. Pulse Biosciences shares last traded at $16.13, with a volume of 55,647 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Price Performance

The business’s 50-day simple moving average is $18.81 and its two-hundred day simple moving average is $18.17.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds have recently bought and sold shares of PLSE. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Pulse Biosciences by 14.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company’s stock valued at $667,000 after purchasing an additional 4,773 shares in the last quarter. Panoramic Capital LLC bought a new stake in shares of Pulse Biosciences in the fourth quarter worth $846,000. Deutsche Bank AG raised its holdings in Pulse Biosciences by 65.1% in the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company’s stock valued at $292,000 after acquiring an additional 6,625 shares in the last quarter. Bank of America Corp DE boosted its stake in Pulse Biosciences by 0.4% during the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company’s stock valued at $13,727,000 after acquiring an additional 2,884 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock worth $29,000 after acquiring an additional 838 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.